Clinical trialNCT05143177TerminatedPhase 2/PHASE3Interventional

A Study to Evaluate the Efficacy and Safety of DA-1229 (Evogliptin) in Patient's Calcific Aortic Valve Disease With Mild to Moderate Aortic Stenosis (EVOID-AS)

SponsorREDNVIA Co., Ltd.Enrollment486Calcific Aortic Valve Disease

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is an adaptive Phase 2/3 multicenter, double-blind, placebo-controlled, randomized, parallel, 2 arm study to evaluate the efficacy and safety of DA-1229 compared to placebo in patients with calcific aortic valve disease with mild to moderate aortic stenosis. There are 2 arms in this study to which patients will be randomized in a ratio of 1:1 to receive the DA-1229 or placebo orally once daily for a period of 104 weeks. The 2 arms are: placebo and DA-1229 10 mg Group. The study will have three phases: Screening Period (up to 4 weeks), Treatment Period (104 weeks), and Follow-Up Period (2-4 weeks). Total Study Duration is112 Weeks.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Jae K Oh, MD
Mayo Clinic
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

25 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Canada

Institut Universitaire de Cardiologie Et de Pneumologie de Québec - Université Laval
Québec, Canada

United States

Mayo Clinic, Az
Phoenix, Arizona, United States
University of Southern California
Los Angeles, California, United States
University of Colorado
Aurora, Colorado, United States
Mayo Clinic, Fl
Jacksonville, Florida, United States
Baycare Health Systems
Safety Harbor, Florida, United States
Northside Hospital
Atlanta, Georgia, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
University of Michigan
Ann Arbor, Michigan, United States
Henry Ford Health System
Detroit, Michigan, United States
Beaumont Hospital, Royal Oak
Royal Oak, Michigan, United States
Mayo Clinic
Rochester, Minnesota, United States
Hackensack Meridian Health
Hackensack, New Jersey, United States
Rutgers- Robert Wood Johnson Medical School
New Brunswick, New Jersey, United States
Ichan School of Medicine
New York, New York, United States
Stony Brook
Stony Brook, New York, United States
Christ Hospital
Cincinnati, Ohio, United States
Ohiohealth Research Institute
Columbus, Ohio, United States
Oregon Health & Science University
Portland, Oregon, United States
University of Pittsburgh Medical Center
Mechanicsburg, Pennsylvania, United States
Einstein Medical Center Philadelphia
Philadelphia, Pennsylvania, United States
Texas Heart Institute
Houston, Texas, United States
the University of Vermont Medical Center
Burlington, Vermont, United States
Inova Health Care Services
Falls Church, Virginia, United States
Aurora Research Institute
Milwaukee, Wisconsin, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

EvogliptinPlacebo

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 27 Jun 2022
Primary completion: 21 Mar 2026
Completion: 26 Mar 2026
Last update posted: 18 Aug 2026
Registered enrollment: 486
Registry id: NCT05143177

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.